XLV
Health Care Select Sector SPDR
Select Sector SPDR® holding S&P 500 stocks in the Health Care sector. Component industries include Health Care Equipment & Services; and Pharmaceutical & Biotechnology. The fund seeks investment results that, before expenses, generally correspond to the price and yield performance of the benchmark index.
US
EQUITY
Passive
MANAGEMENT STYLE
$ 37.4 B
ASSETS UNDER MGMT
8 bp
EXPENSES
Fund Basics
| Inception date | Dec 16, 1998 |
| Regulation | Open-Ended Fund |
| Fund Website | link... |
| Distributions | Quarterly |
| Currency | USD |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | Yes |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
Complete list +
| ELI LILLY & CO | 16.2 % |
| JOHNSON & JOHNSON | 10.0 % |
| ABBVIE INC | 7.1 % |
| UNITEDHEALTH GROUP INC | 6.4 % |
| MERCK & CO. INC. | 5.4 % |
| THERMO FISHER SCIENTIFIC INC | 3.4 % |
| AMGEN INC | 3.4 % |
| GILEAD SCIENCES INC | 3.1 % |
| INTUITIVE SURGICAL INC | 2.8 % |
| PFIZER INC | 2.8 % |
Constituent Breakdown
| Number of holdings | 59 |
| Herfindahl-Hirschman Index | 565 |
| Wgt avg mkt cap (mns) | $314,964 |
| Large cap (>$10bn) | 98.9% |
| Mid cap ($2-10bn) | 0.8% |
| Small cap (<$2bn) | 0.0% |
| Developed mkts. | 99.8% |
| Emerging mkts. | 0.0% |
Sector Breakdown
Country Exposure
 |
UNITED STATES | 97.6 % |
 |
IRELAND | 2.1 % |
Historical Performance
Standardized Performance (as of 05/31/2026)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | -3.4% | 12.7% | 2.0% | 5.4% | 3.9% | 7.7% | 8.3% | 6.7% |
| Dividend Yield | 0.4% | 2.0% | 1.7% | 1.8% | 1.7% | 1.8% | 1.9% | 1.6% |
| Total Returns | -3.0% | 14.7% | 3.7% | 7.1% | 5.6% | 9.5% | 10.2% | 8.3% | Ann. Volatility | 15.0% | 14.6% | 15.3% | 13.9% | 14.7% | 16.5% | 17.0% | 17.8% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 0.49 | 16% |
| MSCI EAFE | 0.49 | 25% |
| MSCI Emg Mkts | 0.22 | 9% |
Liquidity Measures
| Avg. volume (000) | 9,731 |
| ADV traded (mns) | $1,425 |
| Turnover | 3.8% |
| Avg. Bid/Ask (% of price) | 0.01% |
Technical Indicators
| 30d moving avg. (EMA) | $147.23 |
| Relative strength (RSI) | 52 |
| MACD/Signal | 0.88/0.32 |
| Bollinger Bands (Upper/Lower) | $150.78/$142.42 |
| Short interest (% of AUM) | 6.4% |
Distributions
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. XLV |
Expenses vs. XLV |
ALTAR Score™ vs. XLV |
|---|---|---|---|---|
| IYH | iShares U.S. Healthcare ETF | 90.9% | +32 bp | -0.8% |
| VHT | Vanguard Health Care ETF | 85.5% | +1 bp | -1.6% |
| FHLC | Fidelity MSCI Health Care Index ETF | 84.6% | +0 bp | -1.3% |
| IXJ | iShares Global Healthcare ETF | 70.0% | +34 bp | -0.2% |
| HRTS | Tema Heart & Health ETF | 53.2% | +67 bp | -3.9% |
| RSPH | Invesco S&P 500 Equal Weight Health Care ETF | 51.9% | +32 bp | -0.1% |
| FTXH | First Trust Nasdaq Pharmaceuticals ETF | 44.5% | +52 bp | +0.4% |
| MEDX | Horizon Kinetics Medical ETF | 43.0% | +77 bp | -5.8% |
| GDOC | Goldman Sachs Future Health Care Equity ETF | 39.7% | +67 bp | -5.8% |
| PPH | VanEck Pharmaceutical ETF | 38.2% | +28 bp | +0.8% |
Risk and Returns: XLV vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (USD)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 6/3/2026
Peer Group Comparison
Sample data. Subscribe for access.
Historical Valuation Trends Sample data. Subscribe for access.
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
7.3%
ALTAR SCORE™
84th
PERCENTILE
SPECULATIVE
ETFRC RATING
There are 1,399 funds in the US Equity category with an average
ALTAR Score™ of 5.3% and a standard deviation
of 2.1%. XLV's ALTAR Score™ is approximately 1.0 standard
deviations above the category average. This places XLV in the 84th percentile
among funds in the category.
Sell-Side Consensus
$178.33
PRICE TARGET
+21.8%
UPSIDE